NCT05985161 - A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

August 1, 2029

Study Completion Date

August 1, 2029

Conditions

Wilms TumorRhabdoid TumorMalignant Peripheral Nerve Sheath TumorsMPNSTNephroblastomaXPO1 Gene MutationSolid Tumor

Interventions

DRUG

Selinexor

This phase II study will initially treat all patients, including adult patients, at the pediatric Selinexor RP2D of 35 mg/m2 (no maximum dose) once weekly using a liquid suspension .

Trial Locations (15)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All protocol activites), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre

11725

RECRUITING

Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ), Commack

20010

NOT_YET_RECRUITING

Children's National Hospital, Washington D.C.

30322

RECRUITING

Children's Healthcare of Atlanta (Data Collection and Specimen Analysis), Atlanta

45229

RECRUITING

Cincinnati Children's Hospital Medical Center (Data collection only), Cincinnati

60611

RECRUITING

Ann & Robert H. Lurie Children'S Hospital of Chicag, Chicago

63110

RECRUITING

Washington University, St Louis

90027

RECRUITING

Children's Hospital of Los Angeles (Data Collection Only), Los Angeles

94304

NOT_YET_RECRUITING

Standford Medicine Children's Health, Palo Alto

02115

RECRUITING

Dana Farber Cancer Institute (Data Collection Only), Boston

07920

RECRUITING

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited protocol activities), Montvale

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER